Superiority of enviomycin or streptomycin over ethambutol in initial treatment of lung disease caused by Mycobacterium avium complex.
The rate of sputum conversion (continuously negative cultures for six months or more) was compared among four regimens given to 83 patients with moderately advanced, cavitary lung disease caused by Mycobacterium avium complex untreated previously. The regimens of rifampin + isoniazid + enviomycin and rifampin + isoniazid + streptomycin appeared to be superior to the regimen of rifampin + isoniazid + ethambutol. No statistically significant difference was observed between the regimens rifampin + isoniazid + enviomycin and rifampin + isoniazid + streptomycin.
Tsukamura
M
M
Department of Respiratory Disease, National Chubu Hospital, Aichi, Japan.
Ichiyama
S
S
Miyachi
T
T
D002985:Clinical Protocols; D004338:Drug Combinations; D004776:Enviomycin / Q000627:therapeutic use*; D004977:Ethambutol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008171:Lung Diseases / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D015269:Mycobacterium avium Complex / Q000302:isolation & purification; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000627:therapeutic use*; D014756:Viomycin / Q000627:therapeutic use*
D004338:Drug Combinations; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D004776:Enviomycin; D013307:Streptomycin; D014756:Viomycin